• September 25, 2018
    PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) today announced that it has been named one of Working Mother Magazine’s "100 Best Companies for Working Mothers" for the fifth consecutive year. The publication selects the top 100 companies in the U.S. that lead in areas of female representation and advancement, benefits, parental leave, childcare and flexible work arrangements. “We are excited to once again be among Workingmore...
  • September 24, 2018
    PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) will participate in the 2018 Cantor Global Healthcare Conference on Monday, Oct. 1, 2018, in New York, N.Y. Clint Lewis, Executive Vice President and Group President, International Operations, Commercial Development, Genetics and Aquatic Health, will represent the company and respond to questions from analysts. He is scheduled to present at 9:30 a.m. ET. Investors and othermore...
  • August 13, 2018
    PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) today announced that it has agreed to sell $1.5 billion of senior notes, consisting of $300 million aggregate principal amount of floating rate senior notes due 2021, $300 million aggregate principal amount of 3.250% senior notes due 2021, $500 million aggregate principal amount of 3.900% senior notes due 2028 and $400 million aggregate principal amount of 4.450% senior notes due 2048, in anmore...
  • August 2, 2018
    PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) today reported its financial results for the second quarter of 2018 and updated its guidance for full year 2018. The company reported revenue of $1.4 billion for the second quarter of 2018, an increase of 12% compared with the second quarter of 2017. Net income for the second quarter of 2018 was $384 million, or $0.79 per diluted share, an increase of 55% and 58%, respectively, on a reported basismore...
  • July 31, 2018
    PARSIPPANY, N.J. & UNION CITY, Calif.--(BUSINESS WIRE)--Zoetis Inc. (NYSE: ZTS) today announced the completion of the acquisition of Abaxis, a leader in the development, manufacture and marketing of diagnostic instruments for veterinary point-of-care services for US $83 per share in cash, or approximately $2.0 billion in aggregate. The acquisition, which was first announced on May 16, follows the satisfaction of all conditions to the closing, including the receipt of the approval ofmore...
  • July 6, 2018
    PARSIPPANY, N.J. & UNION CITY, Calif.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) and Abaxis, Inc. (NASDAQ:ABAX) today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”), in connection with Zoetis’ previously-announced acquisition of Abaxis for US $83.00 per share in cash, or approximately $2.0 billion in aggregate. The expiration of the waiting period under the HSR Act satisfies one of themore...
  • June 29, 2018
    PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, Aug. 2, 2018. Chief Executive Officer Juan Ramón Alaix and Executive Vice President and Chief Financial Officer Glenn David will review second quarter 2018 financial results and respond to questions from financial analysts during the call. Investors and the public may access the live webcast by visiting the Zoetis website at http://more...
  • June 6, 2018
    PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) will participate in the William Blair 2018 Growth Stock Conference on Tuesday, June 12, 2018, in Chicago, Ill. Juan Ramón Alaix, Chief Executive Officer, will represent the company and respond to questions from analysts. He is scheduled to present at 5:10 p.m. ET (4:10 p.m. CT). Investors and other interested parties will be able to access a live audio webcast of the presentation by visiting http://investormore...
  • June 6, 2018
    Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Zoetis Inc. (NYSE:ZTS) today announced a five-year collaboration to research the use of Regeneron’s monoclonal antibody therapeutics in animals and discover new veterinary treatments.Under the terms of the agreement, Regeneron has granted Zoetis a license for its VelocImmune® antibody technology, which Zoetis will use to develop monoclonal antibodies modified for species-specific use in companion and livestock animals. In particular, Zoetis ismore...
  • May 22, 2018
    PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) will participate in the Stifel 2018 Dental & Veterinary Conference on Wednesday, May 30, 2018, in New York, N.Y. Kristin Peck, Executive Vice President and Group President, U.S. Operations, Business Development and Strategy, will represent the company and respond to questions from analysts. She is scheduled to present at 11:30 a.m. ET. Investors and other interested parties will be able to access a livemore...